Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.

doi:10.1200/JCO.2010.31.0367

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Apr 2011

Yap Timothy A, Olmos David, Brunetto Andre T, Tunariu Nina, Barriuso Jorge, Riisnaes Ruth, Pope Lorna, Clark Jeremy, Futreal Andrew, Germuska Michael, Collins David, deSouza Nandita M, Leach Martin O, Savage Ronald E, Waghorne Carol, Chai Feng, Garmey Edward, Schwartz Brian, Kaye Stan B, de Bono Johann S

Abstract excerpt

PURPOSE: The hepatocyte growth factor/c-MET axis is implicated in tumor cell proliferation, survival, and angiogenesis. ARQ 197 is an oral, selective, non-adenosine triphosphate competitive c-MET inhibitor. A phase I trial of ARQ 197 was conducted to assess safety, tolerability, and target inhibition, including intratumoral c-MET signaling, apoptosis, and angiogenesis. PATIENTS AND METHODS: Patients with solid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Focal Adhesion Kinase 1

Share to Maximum Tolerated Dose

Share to Neoplastic Cells, Circulating

Share to Proto-Oncogene Proteins c-met

Share to Pyrrolidinones

Share to Quinolines

Share to Receptors, Growth Factor

Source

Open in PubMed

Identifiers

PMID: 21383285
DOI: 10.1200/JCO.2010.31.0367

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.PMID 21383285Read ↗

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor ActivitySemantic proximity Read ↗

Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical CandidatesSemantic proximity Read ↗

Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.Semantic proximity Read ↗

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.Semantic proximity Read ↗

Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applicationsSemantic proximity Read ↗

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.Semantic proximity Read ↗

Targeting the c-Met Signaling Pathway in CancerSemantic proximity Read ↗

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.Semantic proximity Read ↗

MET receptor tyrosine kinase as a therapeutic anticancer target.Semantic proximity Read ↗

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.Semantic proximity Read ↗

Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind METSemantic proximity Read ↗

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity <i>in vivo</i>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.